Wendy's stock bolstered as sales guidance offsets weaker-than-expected second-quarter earnings
By Ciara Linnane
An earlier version of this article had the wrong numbers for both quarters as the company's table read from left to right. It has been corrected.
Wendy's Inc. 's stock rose 2.4% early Thursday, after the fast-food company's second-quarter earnings miss was offset by better-than-expected sales guidance.
The Dublin, Ohio-based company had net income of $54.6 million, or 27 cents a share, for the quarter, down from $59.6 million, or 28 cents a share, in the year-earlier period.
Adjusted per-share earnings were 27 cents, a penny below the 28-cent FactSet consensus.
Revenue rose to $570.7 million from $561.6 million a year ago, below the $577.0 million FactSet consensus.
Same-restaurant sales rose 0.8% globally and were up 0.6% in the U.S. The FactSet consensus was for a 2.7% rise.
The company now expects global sales growth of 3% to 5% for 2024, and still expects adjusted EPS to range from 98 cents to $1.02.
The FactSet consensus is for sales to grow 2.7% and for EPS of 99 cents.
The stock was up 1.4% premarket but is down 13% in the year to date, while the S&P 500 has gained 15.8%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
08-01-24 0806ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks